Dechra Pharmaceuticals Plc Stock Price To Earnings To Growth
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
Dechra Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Dechra Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dechra Pink Sheet. The fundamental analysis module provides a way to measure Dechra Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dechra Pharmaceuticals pink sheet.
Dechra |
Dechra Pharmaceuticals PLC Company Price To Earnings To Growth Analysis
Dechra Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Dechra Pharmaceuticals PLC has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—General (which currently averages 0.0) industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Dechra Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dechra Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Dechra Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dechra Pharmaceuticals by comparing valuation metrics of similar companies.Dechra Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.
Dechra Fundamentals
| Return On Equity | 0.0896 | |||
| Return On Asset | 0.0478 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 4.04 B | |||
| Shares Outstanding | 56.92 M | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.99 X | |||
| Price To Sales | 5.65 X | |||
| Revenue | 681.8 M | |||
| Gross Profit | 384.8 M | |||
| EBITDA | 178.9 M | |||
| Net Income | 58.2 M | |||
| Cash And Equivalents | 123.7 M | |||
| Cash Per Share | 2.29 X | |||
| Total Debt | 313.7 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 12.30 X | |||
| Cash Flow From Operations | 122.9 M | |||
| Earnings Per Share | 1.29 X | |||
| Number Of Employees | 2 K | |||
| Beta | 0.68 | |||
| Market Capitalization | 4.3 B | |||
| Total Asset | 1.29 B | |||
| Z Score | 7.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 1.29 B | |||
| Last Dividend Paid | 0.45 |
About Dechra Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dechra Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dechra Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dechra Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |